Lysosomal-targeted doxorubicin delivery using RBC-derived vesicles to overcome drug-resistant cancer through mitochondrial-dependent cell death

• Egile Nagusiak: Chih-Peng Lin (Egilea), Shu-Hui Wu (Egilea), Tzu-Yin Lin (Egilea), Chia-Hui Chu (Egilea), Leu-Wei Lo (Egilea), Ching-Chuan Kuo (Egilea), Jang-Yang Chang (Egilea), Szu-Chun Hsu (Egilea), Bor-Sheng Ko (Egilea), Ming Yao (Egilea), Jong-Kai Hsiao (Egilea), Shih-Wei Wang (Egilea), Dong-Ming Huang (Egilea)
• Formatua: Liburua
• Argitaratua: Elsevier, 2023-11-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Multidrug resistance (MDR) is a major challenge in cancer chemotherapy. Nanoparticles as drug delivery systems (DDSs) show promise for MDR cancer therapy. However, current DDSs require sophisticated design and construction based on xenogeneic nanomaterials, evoking feasibility and biocompatibility c...